Literature DB >> 14506162

Overexpression of E2F-1 is associated with increased disease-free survival in squamous cell carcinoma of the anterior tongue.

Rhonda A Kwong1, Tuan V Nguyen, Ronaldo J Bova, James G Kench, Ian E Cole, Elizabeth A Musgrove, Susan M Henshall, Robert L Sutherland.   

Abstract

PURPOSE: Overexpression of E2F-1 is associated with increased invasiveness in head and neck squamous cell carcinoma cell lines in vitro, but its significance in vivo is unknown. This study sought to determine the relationship between E2F-1 and retinoblastoma protein (pRb) expression and disease outcome in squamous cell carcinoma (SCC) of the anterior tongue. EXPERIMENTAL
DESIGN: pRb and E2F-1 protein expression was assessed by immunohistochemistry in a cohort of 145 patients with SCC of the anterior tongue. The outcomes examined were time to disease recurrence or death. The relationships between E2F-1 or pRb expression and outcome were assessed by univariate and multivariate Cox's proportional hazards model, with or without clinicopathological covariates, including nodal status, disease stage, treatment status, and molecular markers (cyclin D1, p16(INK4A), and Ki-67) previously measured in this cohort.
RESULTS: On univariate analysis, increased expression of E2F-1 (>35% of positive-stained nuclei) was associated with increased disease-free survival (DFS; hazard ratio [HR]: 0.35; P = 0.04) and increased overall survival (OS; HR: 0.33; P = 0.06). Decreased expression of pRb (<50% positive nuclei) was associated with increased DFS (HR: 1.81; P = 0.06) but not with OS (P = 0.11). However, when considered simultaneously with other significant factors, i.e. lymph node status, p16(INK4A) protein expression, and histopathological grade, in the multivariate Cox's proportional hazards model, the additional contributions of E2F-1 and/or pRb expression to DFS and OS were not statistically significant.
CONCLUSIONS: These data demonstrate that in patients with SCC of the tongue, overexpression of E2F-1 is associated with increased DFS and OS. However, this association is not independent of lymph node status, tumor grade, and p16(INK4A) expression. Among the cell cycle-regulatory molecules studied, p16(INK4A) expression is the most predictive molecular marker of disease outcome.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14506162

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  10 in total

1.  SUZ12 is involved in progression of non-small cell lung cancer by promoting cell proliferation and metastasis.

Authors:  Chunhua Liu; Xuefei Shi; Li Wang; Ying Wu; Feiyan Jin; Cuiqing Bai; Yong Song
Journal:  Tumour Biol       Date:  2014-03-15

2.  Prognostic value of E2F1 in rectal cancer.

Authors:  Hasan Uzer; Hızır Akyıldız; Erdoğan Sözüer; Alper Akcan; Bahadır Öz
Journal:  Turk J Surg       Date:  2017-09-01

3.  Carcinoma of tongue and the buccal mucosa represent different biological subentities of the oral carcinoma.

Authors:  K M Sathyan; R Sailasree; R Jayasurya; K Lakshminarayanan; Thomas Abraham; K R Nalinakumari; Elizabeth K Abraham; S Kannan
Journal:  J Cancer Res Clin Oncol       Date:  2006-06-10       Impact factor: 4.553

4.  Increased E2F-1 expression via tumour cell proliferation and decreased apoptosis are correlated with adverse prognosis in patients with squamous cell carcinoma of the oesophagus.

Authors:  K Yamazaki; M Hasegawa; I Ohoka; K Hanami; A Asoh; T Nagao; I Sugano; Y Ishida
Journal:  J Clin Pathol       Date:  2005-09       Impact factor: 3.411

Review 5.  Emerging roles of E2Fs in cancer: an exit from cell cycle control.

Authors:  Hui-Zi Chen; Shih-Yin Tsai; Gustavo Leone
Journal:  Nat Rev Cancer       Date:  2009-11       Impact factor: 60.716

6.  The retinoid signalling molecule, TRIM16, is repressed during squamous cell carcinoma skin carcinogenesis in vivo and reduces skin cancer cell migration in vitro.

Authors:  Belamy B Cheung; Jessica Koach; Owen Tan; Patrick Kim; Jessica L Bell; Carla D'andreti; Selina Sutton; Alena Malyukova; Eric Sekyere; Murray Norris; Michelle Haber; Maria Kavallaris; Anne M Cunningham; Charlotte Proby; Irene Leigh; James S Wilmott; Caroline L Cooper; Gary M Halliday; Richard A Scolyer; Glenn M Marshall
Journal:  J Pathol       Date:  2011-10-18       Impact factor: 7.996

7.  Transcription factor E2F1 positively regulates interferon regulatory factor 5 expression in non-small cell lung cancer.

Authors:  Dan-Dan Feng; Qian Cao; Dao-Qi Zhang; Xiao-Lu Wu; Cai-Xia Yang; Yu-Fei Chen; Tang Yu; Hai-Xiao Qi; Guo-Ping Zhou
Journal:  Onco Targets Ther       Date:  2019-08-23       Impact factor: 4.147

8.  Clinical significance of E2F1 protein expression in non-small cell lung cancer.

Authors:  Jung-Jyh Hung; Chung-Tsen Hsueh; Kuan-Hua Chen; Wen-Hu Hsu; Yu-Chung Wu
Journal:  Exp Hematol Oncol       Date:  2012-07-20

Review 9.  Transcription addiction: can we garner the Yin and Yang functions of E2F1 for cancer therapy?

Authors:  P Meng; R Ghosh
Journal:  Cell Death Dis       Date:  2014-08-07       Impact factor: 8.469

10.  E2F1 mediated DDX11 transcriptional activation promotes hepatocellular carcinoma progression through PI3K/AKT/mTOR pathway.

Authors:  Yan Yu; Dan Zhao; Kongfei Li; Yubo Cai; Penglin Xu; Rui Li; Juan Li; Xiaolong Chen; Ping Chen; Guangying Cui
Journal:  Cell Death Dis       Date:  2020-04-24       Impact factor: 8.469

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.